Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

What are the considerations in patient selection and timing of risk-reducing mastectomy?

Holly J. Pederson, MD, Allison W. Kurian, MD, MSc and Zahraa Al Hilli, MD
Cleveland Clinic Journal of Medicine August 2022, 89 (8) 442-444; DOI: https://doi.org/10.3949/ccjm.89a.21114
Holly J. Pederson
Director, Medical Breast Services, Cleveland Clinic Breast Center, Cleveland Clinic, Cleveland, OH; Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Former Member of the National Comprehensive Cancer Center Committees for Breast Cancer Risk Reduction and Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
Allison W. Kurian
Departments of Medicine and of Epidemiology & Population Health, Stanford University, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zahraa Al Hilli
Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

In patients with pathogenic or likely pathogenic genetic variants in high-risk genes (BRCA1, BRCA2, PALB2, PTEN, TP53, and CDH1), compelling family history, or a history of thoracic radiation therapy before age 30, risk-reducing mastectomy is an option to be discussed in addition to effective screening and risk-reducing medications. Owing to possible morbidity, impact on body image, psychological distress, and loss of chest-wall sensation, patient selection and shared decision-making are critical to determine optimal patient choices. The option of risk-reducing mastectomy is for those at the highest levels of risk, and multidisciplinary conversations setting patient expectations are critical for optimal patient outcomes.

BREAST CANCER RISK AND RISK-REDUCING MASTECTOMY

Breast cancer remains the most common solid tumor in women, making it critical to identify patients with highly penetrant germline genetic variants early, as cancers often begin to develop at age 30.1 The 3 pillars of risk management for high-risk women include enhanced surveillance (the addition of contrast-enhanced magnetic resonance imaging to mammography, often alternating every 6 months), risk-reducing medication (selective estrogen-receptor modulators such as tamoxifen or raloxifene, or aromatase inhibitors such as anastrozole or exemestane), and risk-reducing mastectomy.

Patients may be over-treated with surgery; it is critical for both clinicians and patients to understand cancer risks and recommendations. That being said, most surgical patients are satisfied with their decision given the reduced risk of breast cancer of at least 90%.2 No randomized studies have compared enhanced surveillance with surgery. Modeling studies have suggested a 6% to 8% mortality reduction for patients with BRCA1 carriers and 3% for BRCA2 carriers.3,4

HOW TO DISCUSS WITH THE PATIENT?

The decision to undergo risk-reducing mastectomy is highly personal and should not be introduced as a clinician’s recommendation. Rather, patients should be presented with the risks and benefits of each option including effective screening for high-risk patients, risk-reducing medications, and risk-reducing mastectomy to make their own informed choice. Further, risk-reducing bilateral salpingo-oophorectomy has been recommended for BRCA1/2 carriers as screening is neither sensitive nor specific enough to detect early-stage ovarian cancer.2

Guidelines

According to guidelines from the National Comprehensive Cancer Network, the National Cancer Institute, and the American College of Obstetrics and Gynecology, risk-reducing mastectomy should generally be considered only in individuals with a pathogenic or likely pathogenic variant (not a variant of uncertain significance) conferring a high risk for breast cancer, compelling family history, or possibly with a past history of thoracic radiation therapy under age 30 (such as mantle radiation for treatment of Hodgkin lymphoma).5 The value of risk-reducing mastectomy in individuals with pathogenic or likely pathogenic variants in moderate risk genes (such as CHEK2 or ATM) in the absence of a compelling family history of breast cancer is unknown.6 While risk-reducing mastectomy has been previously considered for lobular carcinoma in situ, the preferred approach currently is risk-reducing medication given its effectiveness.5

Gene carriers and risk

There are 6 gene carriers for which a discussion about risk-reducing mastectomy is indicated due to their absolute estimated risk of developing breast cancer: BRCA1 (72%),1 BRCA2 (69%),1 PALB2 (up to 53%),7 PTEN (up to 85%),8 CDH1 (43%),9 and TP53 (85%).8,10 Some patients have clinical features of Cowden syndrome but test negative for a PTEN mutation (clinical Cowden syndrome). These patients are felt to be at lower risk for breast cancer,11 and consideration of risk-reducing mastectomy should be based on family history.6 Excellent long-term results have been reported for bilateral nipple-sparing mastectomy for breast cancer risk-reduction in appropriate patients.12

Genes for which evidence is insufficient for risk-reducing mastectomy and those to be managed based on family history include CHEK2, NF1, STK11, ATM, and BARD1. Genes for which there is insufficient data, where management (including magnetic resonance imaging screening) is based on family history include BRIP1, RAD51C, and RAD51D.6,13

Treatment determination

The risk associated with many genetic variants decreases with age,1 and patient selection is critical. Regarding timing, the risk of breast cancer is quite low under the age of 30, and the residual risk decreases after the age of 50.1 Older women should be advised that their residual risk declines with age, informing decision-making. The benefit of risk-reducing mastectomy may be offset by operative risks and other causes for mortality.1,14 There is no absolute age at which risk-reducing mastectomy is no longer recommended. However, it is important to provide age-specific cancer risk estimates to determine appropriate interventions.1,14 In a recent study, the cumulative risk of invasive breast cancer in women ages 60 to 80 was 20.1% for BRCA1 carriers and 17.3% for BRCA2 carriers.1,14

Chemoprevention is a risk management alternative, although BRCA1 carriers under age 50 are predisposed to triple-negative breast cancer, and preventive medication is likely to offer little benefit.1,5,13,15 Older women with BRCA1 are more commonly diagnosed with estrogen-receptor−positive disease,16 and it is reasonable to offer preventive medication to BRCA1 carriers over age 50.2 RAD51C and RAD51D carriers are predisposed to estrogen-receptor−negative disease and may not benefit from preventive therapy.17

BRCA, OVARIAN CANCER, AND BREAST CANCER

Women with BRCA mutations who have developed ovarian cancer, the most lethal gynecologic malignancy,18 have an overall 5-year survival rate of 45.6%.19 Experts suggest that women with stage I ovarian cancer who are disease-free for at least one year, are most likely to benefit from risk-reducing mastectomy.7,18,20 In patients with stage II/III disease, BRCA mutation carriers have a relatively low risk of breast cancer and their prognosis is largely determined by their ovarian cancer diagnosis. Studies show a 2% to 6% incidence of breast cancer in the first 5 years and an approximate 10% risk in the first 10 years following epithelial ovarian cancer diagnosis.7,18,20,21 The risk of breast cancer is lower in ovarian cancer survivors who carry BRCA mutations than that reported for BRCA carriers who have not developed ovarian cancer (possibly due to oophorectomy or use of chemotherapy that could eliminate microscopic breast cancer at the cellular level).

Consideration of risk-reducing mastectomy after ovarian cancer diagnosis

In a modelling study by Gamble et al,20 the added gain in survival benefit in months following risk-reducing mastectomy, if performed in the first several years after an ovarian cancer diagnosis, was small and greatest in women under 50.20 The study also noted that risk-reducing mastectomy is not indicated within 5 years of an ovarian cancer diagnosis due to a high rate of ovarian cancer relapse.20 It has been suggested that consideration of risk-reducing mastectomy for BRCA carriers be reserved for those who remain in remission for 5 years,7 and possibly for women age 50 or younger at ovarian cancer diagnosis.18,22 Furthermore, a study of 1,455 women who developed primary breast cancer after ovarian cancer showed mean time from ovarian cancer diagnosis to breast cancer diagnosis of 7.3 years.23

TAKE-HOME POINTS

  • Discuss the option of risk-reducing mastectomy in patients with pathogenic or likely pathogenic variants in BRCA1, BRCA2, PALB2, PTEN, TP53 and CDH1.

  • Consider risk-reducing mastectomy in patients with compelling family history or with a past history of thoracic radiation therapy under the age of 30.

  • Discuss the option of risk-reducing mastectomy in BRCA carriers following an ovarian cancer diagnosis only after 5 years of remission.

THE BOTTOM LINE

Although most women who choose to undergo risk-reducing mastectomy are generally satisfied with their decision, many report adverse impact on body image and sexual relationships, and emotional distress due to a sense of loss and abnormal chest-wall sensation. Despite constant improvements in reconstructive cosmetic outcomes, there is considerable morbidity related to the procedure, and patient selection is critical for optimal results. Shared decision-making is key. Risk-reducing mastectomy is for patients with the highest levels of risk, and multidisciplinary conversations setting patient expectations are critical for optimal patient outcomes.

DISCLOSURES

Dr. Pederson has disclosed consulting for Myriad Genetics. Dr. Kurian and Dr. Al Hilli report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Kuchenbaecker KB,
    2. Hopper JL,
    3. Barnes DR, et al
    . Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317(23):2402–2416. doi:10.1001/jama.2017.7112
    OpenUrlCrossRefPubMed
  2. ↵
    1. Li X,
    2. You R,
    3. Wang X, et al
    . Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res 2016; 22(15):3971–3981. doi:10.1158/1078-0432.CCR-15-1465
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Kurian AW,
    2. Sigal BM,
    3. Plevritis SK
    . Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28(2):222–231. doi:10.1200/JCO.2009.22.7991
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Giannakeas V,
    2. Narod SA
    . The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat 2018; 167(1):263–267. doi:10.1007/s10549-017-4476-1
    OpenUrlCrossRef
  5. ↵
    1. National Comprehensive Cancer Network
    . NCCN guidelines: detection, prevention, and risk reduction. Breast cancer risk reduction. https://www.nccn.org/guidelines/category_2. Accessed May 13, 2022.
  6. ↵
    1. Daly MB,
    2. Pal T,
    3. Berry MP, et al
    . Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19(1):77–102. doi:10.6004/jnccn.2021.0001
    OpenUrlCrossRefPubMed
  7. ↵
    1. Peters ML,
    2. Garber JE,
    3. Tung N
    . Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecol Oncol 2017; 146(1):205–214. doi:10.1016/j.ygyno.2017.04.013
    OpenUrlCrossRef
  8. ↵
    1. Tan M-H,
    2. Mester JL,
    3. Ngeow J,
    4. Rybicki LA,
    5. Orloff MS,
    6. Eng C
    . Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18(2):400–407. doi:10.1158/1078-0432.CCR-11-2283
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Xicola RM,
    2. Li S,
    3. Rodriguez N, et al
    . Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019;56(12):838–843. doi:10.1136/jmedgenet-2019-105991
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Mai PL,
    2. Best AF,
    3. Peters JA, et al
    . Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li–Fraumeni syndrome cohort. Cancer 2016; 122:3673–3681. doi:10.1002/cncr.30248
    OpenUrlCrossRefPubMed
  11. ↵
    1. Tan M-H,
    2. Mester J,
    3. Peterson C, et al
    . A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88(1):42–56. doi:10.1016/j.ajhg.2010.11.013
    OpenUrlCrossRefPubMed
  12. ↵
    1. Grobmyer SR,
    2. Pederson HJ,
    3. Valente SA, et al
    . Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy. BJS Open 2018; 3(2):169–173. doi:10.1002/bjs5.50117
    OpenUrlCrossRef
  13. ↵
    1. National Comprehensive Cancer Network
    . Clinical Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic. v2.2022. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed May 13, 2022.
  14. ↵
    1. Stjepanovic N,
    2. Lubinski J,
    3. Moller P, et al
    . Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2021; 187(2):515–523. doi:10.1007/s10549-020-06072-9
    OpenUrlCrossRef
  15. ↵
    1. King MC,
    2. Wieand S,
    3. Hale K, et al
    . Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NS-ABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286(18):2251–2256. doi:10.1001/jama.286.18.2251
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hu C,
    2. Polley EC,
    3. Yadav S, et al
    . The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst 2020; 112(12):1231–1241. doi:10.1093/jnci/djaa023
    OpenUrlCrossRef
  17. ↵
    1. Hu C,
    2. Hart SN,
    3. Gnanaolivu R, et al
    . A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021; 384(5):440–451. doi:10.1056/NEJMoa2005936
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wahner Hendrickson AE,
    2. Bakkum-Gamez JN,
    3. J Couch F,
    4. Ghosh K,
    5. Boughey JC
    . Management of breast cancer risk in women with ovarian cancer and deleterious BRCA1 or BRCA2 mutations. Ann Surg Oncol 2017; 24(11):3107–3109. doi:10.1245/s10434-017-5999-8
    OpenUrlCrossRef
  19. ↵
    1. Howlader N,
    2. Noone AM,
    3. Krapcho M, et al; National Cancer Institute
    . Surveillance, Epidemiology, and End Results Program. SEER cancer statistics review, 1975–2014. Bethesda, MD: April 2017. https://seer.cancer.gov/archive/csr/1975_2014/. Accessed May 13, 2022.
  20. ↵
    1. Gamble C,
    2. Havrilesky LJ,
    3. Myers ER, et al
    . Cost effectiveness of risk-reducing mastectomy versus surveillance in BRCA mutation carriers with a history of ovarian cancer. Ann Surg Oncol 2017; 24(11):3116–3123. doi:10.1245/s10434-017-5995-z
    OpenUrlCrossRef
  21. ↵
    1. Gangi A,
    2. Cass I,
    3. Paik D, et al
    . Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg 2014; 149(12):1306–1313. doi:10.1001/jamasurg.2014.1081
    OpenUrlCrossRef
  22. ↵
    1. Domchek SM,
    2. Jhaveri K,
    3. Patil S, et al
    . Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 2013; 119(7):1344–1348. doi:10.1002/cncr.27842
    OpenUrlCrossRef
  23. ↵
    1. Zhang W,
    2. Zhang W,
    3. Lin Z, et al
    . Survival outcomes of patients with primary breast cancer following primary ovarian cancer. Med Sci Monit 2019; 25:3869–3879. doi:10.12659/MSM.914163
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (8)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 8
1 Aug 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
What are the considerations in patient selection and timing of risk-reducing mastectomy?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What are the considerations in patient selection and timing of risk-reducing mastectomy?
Holly J. Pederson, Allison W. Kurian, Zahraa Al Hilli
Cleveland Clinic Journal of Medicine Aug 2022, 89 (8) 442-444; DOI: 10.3949/ccjm.89a.21114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What are the considerations in patient selection and timing of risk-reducing mastectomy?
Holly J. Pederson, Allison W. Kurian, Zahraa Al Hilli
Cleveland Clinic Journal of Medicine Aug 2022, 89 (8) 442-444; DOI: 10.3949/ccjm.89a.21114
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • BREAST CANCER RISK AND RISK-REDUCING MASTECTOMY
    • HOW TO DISCUSS WITH THE PATIENT?
    • BRCA, OVARIAN CANCER, AND BREAST CANCER
    • TAKE-HOME POINTS
    • THE BOTTOM LINE
    • DISCLOSURES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Reducing the risk of breast cancer
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Oncology
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire